The current understanding of the benefits, safety, and regulation of cannabidiol in consumer products
The popularity of cannabidiol (CBD) in consumer products is soaring as consumers are using CBD for general health and well-being as well as to seek relief from ailments especially pain, inflammation, anxiety, depression, and sleep disorders. However, there is limited data currently in the public domain that provide support for these benefits. By contrast, a significant amount of safety evaluation data for CBD has been obtained recently from pre-clinical and clinical studies of the CBD therapeutic Epidiolex®. Yet some key data gaps concerning the safe use of CBD still remain. Furthermore, current regulations on CBD use in consumer products remain uncertain and often conflict between the state and federal level. In light of the rapidly expanding popularity of CBD-related products in the marketplace, here we review the current understanding of the benefits, safety, and regulations surrounding CBD in consumer products. This review does not advocate for or against the use of CBD in consumer products. Rather this review seeks to assess the state-of-the-science on the health effects and safety of CBD, to identify critical knowledge gaps for future studies, and to raise the awareness of the current regulations that govern CBD use in consumer products.
Keywords: CBD regulations; Cannabidiol; Cannabinoid; Consumer products; Hemp; Ingredient safety.
Copyright © 2021. Published by Elsevier Ltd.
Conflict of interest statement
Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. JL and LB declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. RC provides legal advice to companies that manufacture and/or distribute products that contain CBD. NEK has received research funding from and also serves on the Scientific Advisory Committee for GB Sciences Global Biopharma.